Odyssey Health, Inc.

Equities

ODYY

US67612C1027

Delayed OTC Markets Other stock markets 11:48:29 26/06/2024 pm IST			5-day change	1st Jan Change
0.04 ^USD	-18.20%		-26.74%	-60.00%

14/06	Odyssey Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024	CI
22/03	Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI

Jacob Van Landingham to Join Board of Directors of Odyssey

June 28, 2019 at 05:49 pm IST

On June 27, 2019, Odyssey Group International, Inc. entered into a Definitive Agreement with Prevacus, Inc. to form a Joint Venture relating to the development of a neurosteroid for treating two orphan disorders, Amyotrophic Lateral Sclerosis (ALS) and Nieman Picks disease. As part of the Definitive Agreement, Dr. Jacob Van Landingham Ph.D., CEO of Prevacus, will join the Board of Directors of Odyssey.

Latest news about Odyssey Health, Inc.

Odyssey Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024	15/06	CI
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	23/03	CI
Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	28/12	CI
Odyssey Health, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	16/12	CI
Odyssey Health, Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	31/23/31	CI
Odyssey Health, Inc. Announces the Resignation of John Gandolfo as Director	07/23/07	CI
Oragenics, Inc. entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	05/23/05	CI
Odyssey Health, Inc. Presents Concussion Treatment Data At the Military Health System Research Symposium -MHSRS	23/23/23	CI
Odyssey Health, Inc. executed a non- binding letter of intent to acquire Speranza Therapeutics, Inc.	28/23/28	CI
Odyssey Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	15/23/15	CI
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	18/23/18	CI
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	18/23/18	CI
Odyssey Health, Inc. Appoints Jeffrey Conroy as Director	14/23/14	CI
Odyssey Health, Inc. to Develop Intranasal Field- Deliverable Nerve Agent Antidote	12/23/12	CI
Odyssey Health, Inc. Announces Resignation of Jeffrey Conroy as Director	07/23/07	CI
Odyssey Health, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2022	15/22/15	CI
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development	23/22/23	CI
Odyssey Health Inc. Announces Expansion of Executive Team	03/22/03	CI
Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device	01/22/01	CI
Odyssey Health, Inc. Reports Earnings Results for the Full Year Ended July 31, 2022	01/22/01	CI
Odyssey Health, Inc. Auditor Raises 'Going Concern' Doubt	31/22/31	CI
Odyssey Health, Inc. Forms Pharmaceutical Subsidiary Focused on Treating Neurological Diseases	11/22/11	CI
Odyssey Health, Inc. Decides to Dissolve its Sports Advisory Board	03/22/03	CI
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug	28/22/28	CI
Odyssey Health, Inc. Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II	13/22/13	CI

Chart Odyssey Health, Inc.

Duration

Period

More charts

Company Profile

Sector

More about the company

Income Statement Evolution

More financial data